Allopurinol and Quality of Life in Liver Cirrhosis

Phase 2

Completed

• Conditions: Cirrhosis, Liver
• Interventions: Drug: Allopurinol Tablet; Drug: Placebo

• Registration Number: NCT05828836
• Lead Sponsor: Tanta University

Brief Summary

The study aims to evaluate the impact of allopurinol on patients' related quality of life.

Detailed Description

Cirrhosis is the late stage of liver damage and possess two phases:. The shift from compensated to decompensated cirrhosis is characterized by the onset of complications) which are associated with substantial morbidity and negative Impact on quality of life (QOL)Cirrhosis and its complications have a substantial economic, social, and personal impact on affected patients, as well as their families and caregivers

Study Timeline

• Study Start: 2022-06-15
• Primary Completion: 2023-01-15
• Study Completion: 2023-03-01
• Study First Submitted: 2023-04-12
• Study First Submitted QC: 2023-04-12
• Study First Posted: 2023-04-25
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-29
• Last Update Posted: 2023-10-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

cirrhosis adult both sex

Exclusion Criteria

• renal insufficiency

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
allopurinol	Allopurinol Tablet	-
placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Chronic liver disease questionnaire	6 months	effect on Chronic liver disease questionnaire score

Trial Locations

Locations (1)

Faculty of Pharmacy; 🇪🇬 Tanta, Egypt